-
NAMSA to Acquire WuXi AppTec’s US Medical Device Testing Business
•
US-based medical device contract research organization (CRO) NAMSA is set to acquire the medical device testing business in the US of China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259). The acquisition includes two factories located in Minnesota and Georgia. According to the agreement, for which…
-
Inscinstech Secures C-Series Financing for Biopharma Expansion
•
Inscinstech Co., Ltd., a leading intelligent technology company based in Suzhou, has successfully completed a C-series financing round worth hundreds of millions of RMB. The round was led by the Service Trade Innovation Development Guidance Fund, with additional investments from ORIZA Holdings and LUCION, an existing shareholder. This financing marks…
-
Raytone Bio Completes Angel Round to Advance iSus® Platform
•
Raytone Bio, a Shenzhen-based biopharmaceutical company, has announced the completion of a multi-million RMB Angel Round Funding. The round was led by Qianhai Triwise International Capital Management Co., Ltd., National Medical Equipment Development (NMED) Innovation Center, JenKem Technology Co., Ltd. (SHA: 688356), and Dalton Venture, with exclusive financial advisory services…
-
IVIEW Therapeutics Secures Series A++ Funding for Ophthalmology Pipeline
•
IVIEW Therapeutics Inc., an ophthalmology biotech operating out of the US and China, has reportedly raised an undisclosed amount of funds via a Series A++ financing round. The round was led by Chongqing Changsheng Shenghe Investment Fund, with contributions from Hangzhou Jiurun Investment, ehroh, and existing investors Proxima Ventures Fund…
-
a16z Bio + Health Launches Biotech Ecosystem Venture Fund
•
Andreessen Horowitz (a16z) Bio + Health has announced the establishment of the Biotech Ecosystem Venture Fund, a venture capital fund backed by Eli Lilly and Company (NYSE: LLY). The fund is designed to drive transformative progress in healthcare by investing in therapeutic platforms and cutting-edge technology companies that can bring…
-
Servier and Google Cloud Extend Partnership to Advance AI in Drug Development
•
France-based Servier Group and US technology firm Google Cloud have announced an expansion to their five-year partnership, initially struck in August 2022, by an additional five years. The extension aims to enhance the research and development (R&D) of innovative therapeutic solutions for patients through the utilization of AI and generative…
-
Cathay Biotech Plans $901M Private Placement to Boost Bio-Based Materials
•
Shanghai-based Cathay Biotech Inc. (SHA: 688065) has announced plans to raise RMB 6.6 billion (USD 901 million) through a private placement of 153,595,531 shares at RMB 42.97 (USD 5.86) per share. This significant capital raise is aimed at enhancing the company’s capabilities in the research, development, manufacturing, and sales of…
-
ConjuStar Completes $15 Million Pre-A+ Financing Round
•
ConjuStar, a clinical-stage biotechnology company based in Tianjin, China, has announced the completion of a Pre-A+ financing round totaling RMB 100 million (approximately USD 15 million). The round was led by Fosun Health Capital’s New Drug Innovation Fund, with participation from Hengqin Venture Capital and Shenzhen Qianhai Liyuan. Funding and…
-
Gentize Biopharma Raises $13.64M in Pre-Series A for Vaccine Development
•
Gentize Biopharma, a clinical-stage vaccine developer based in Nanjing, has reportedly raised close to RMB 100 million (USD 13.64 million) in a Pre-Series A financing round. The round was solely funded by Hyfinity Investments, highlighting the investor’s confidence in Gentize’s innovative vaccine portfolio. Financing and Future PlansThe proceeds from this…
-
Neo Modulus Secures $40.9M Series C Funding for Regenerative Medical Devices
•
Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd., a prominent developer of regenerative implantable medical devices in China, has announced the successful completion of its Series C financing round, raising RMB 300 million (USD 40.9 million). The round was led by the SCGC Manufacturing Industry Transformation and Upgrading to New Materials…
-
Ouro Medicines Launches with $120M Series A Financing for CM336 Development
•
Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.’s (HKG: 2162) CM336, has successfully launched with a USD 120 million Series A financing round. The California-headquartered biotech, founded by Monograph Capital in partnership with GSK plc (NYSE: GSK), saw the funding co-led by TPG Life Sciences Innovations, NEA, and Norwest…
-
Shenzhen Oculgen Secures Over RMB 100 Million in Series A Funding
•
Shenzhen Oculgen Biomedical Technology Co., Ltd. has successfully completed a Series A financing round, raising over RMB 100 million (USD 14.46 million). The round was led by LongRiver Jiangyuan Investment, with additional participation from Nanshan Zhanxin Investment, Junshi Venture Capital, Boyuan Capital, and Qingsong Capital. Existing investor Genesis Venture also…
-
Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development
•
China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm Timberlyne Therapeutics, Inc., granting the startup biopharma exclusive development, manufacturing, and commercialization rights to its CM313, a CD38-targeted monoclonal antibody (mAb). The agreement covers global rights, excluding mainland China, Hong Kong, Macau, and Taiwan. Financial…
-
Immunochina Pharmaceuticals Raises Series E Funding for CAR-T Therapy IM19
•
Beijing-based biotech Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series E financing round. The round was led by BTH Coordinated Development Industrial Investment Fund, with contributions from Taiping Medical and Health Industry Equity Investment Fund, Beijing Science and Technology Innovation Group, Beijing Sun-Novo Pharmaceutical Research…
-
Danaher Corporation Partners with Innovaccer to Enhance Healthcare AI Solutions
•
US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced an investment partnership with Innovaccer Inc., a leading Silicon Valley-based healthcare artificial intelligence (AI) company. The alliance is designed to improve patient prognosis and experience through innovative digital solutions. Innovaccer’s SolutionsInnovaccer offers a suite of software solutions designed…
-
Verdiva Bio Launches with USD 411 Million Series A Financing for Biopharma Development
•
UK-based Verdiva Bio Limited has announced its launch as a clinical-stage biopharma company, backed by an oversubscribed Series A financing of USD 411 million. The round was co-led by Forbion and General Atlantic, with additional investments from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital. Product…
-
Stryker to Acquire Inari Medical for USD 4.9 Billion to Boost VTE Pipeline
•
US-based Stryker (NYSE: SYK) has reached a definitive acquisition agreement with compatriot firm Inari Medical, Inc. (NASDAQ: NARI), purchasing all issued and outstanding shares at USD 80 per share in cash. The transaction amounts to a total fully diluted equity value of approximately USD 4.9 billion. Inari Medical’s PortfolioFounded in…
-
Insilico Medicine Raises USD 100 Million in Financing Round Led by Pudong and Hong Kong
•
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has reportedly raised USD 100 million in a new financing round. This marks the first joint investment effort between Shanghai’s Pudong district and Hong Kong in the biopharma sector. The initiative follows a partnership established in December 2023 between Shanghai Pudong Development…
-
Boston Scientific Set to Acquire Bolt Medical for Up to USD 900 Million
•
US major Boston Scientific Corporation (NYSE: BSX) is set to acquire Bolt Medical, Inc., a company founded in 2019 with Boston Scientific’s backing, in which it currently holds a 26% stake. The transaction is structured to include an upfront payment of USD 43 million for the remaining 74% ownership that…
-
LinkedCare Raises Hundreds of Millions in Series E Funding Led by State-Owned Investors
•
LinkedCare, a consumer healthcare SaaS+ supply chain platform based in Shanghai, has reportedly raised “hundreds of millions” of renminbi in a Series E financing round. The funding was led by Wuxi Venture Capital and BHIDG, both state-owned enterprises. This investment will support the company’s ongoing expansion and innovation in the…
